TLX Telix Pharmaceuticals Limited
Price Chart
Executive Summary
Telix presented Phase 3 ProstACT Global Part 1 safety data at ASCO 2026 for TLX591-Tx in mCRPC, showing acceptable tolerability with standard-of-care combinations and no new safety signals. The data support advancing to Part 2 randomized expansion, with FDA engagement underway for U.S. enrollment. This is a positive clinical milestone for a first-in-class rADC candidate, but the stock impact is tempered by early-stage data and no near-term approval catalyst.
Actionable Insight
The positive Part 1 safety data de-risks TLX591-Tx's combination profile and supports continued Phase 3 enrollment. Monitor FDA IND amendment decision and Part 2 enrollment updates as key catalysts. The differentiated liver-clearance mechanism could provide competitive advantage over existing PSMA RLTs if confirmed in larger randomized data.
Key Facts
- Part 1 data from 36 patients showed acceptable safety across all SoC combination cohorts (abiraterone, enzalutamide, docetaxel) with no new safety signals.
- All 36 patients received both doses of TLX591-Tx per protocol; hematologic events (Grade 3-4 thrombocytopenia/neutropenia) were transient and consistent with class profile.
- Dosimetry showed radiation exposure to key organs well below established safety limits; highest absorbed dose in liver (1.62-5.08 mGy/MBq), low salivary gland uptake (0.001-0.104 mGy/MBq).
- Part 2 randomized 2:1 expansion is actively dosing in Australia, New Zealand, Canada, Turkey, UK, with approvals in China, Singapore, South Korea; FDA engagement underway for U.S. IND amendment.
- TLX591-Tx is a first-in-class lutetium rADC with differentiated pharmacology (liver clearance, minimal kidney/salivary toxicity) vs. existing PSMA-targeted small molecule RLTs.
Financial Impact
No financial data provided; TLX591-Tx has not received marketing authorization in any jurisdiction.
Risk Factors
- Part 2 randomized data (n~490) may not replicate Part 1 safety profile or show efficacy benefit vs. SoC alone.
- Regulatory delays in U.S. IND amendment could slow enrollment and timeline.
- Competition from approved PSMA-targeted RLTs (e.g., Pluvicto) with established commercial presence.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304754 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
10d ago
|
Press Release
| $9.16 $8.77 | ▼ −4.26% | ▼ −3.54% | $9.56 (+4.37%) |
|
Jun 1, 2026
11d ago
|
Press Release
| $9.16 $8.77 | ▼ −4.26% | ▼ −3.54% | $9.56 (+4.37%) |
|
May 18, 2026
25d ago
|
Press Release
| $10.17 $10.28 | ▲ +1.08% | ▲ +0.04% | $9.56 (−6.00%) |
|
May 15, 2026
28d ago
|
Press Release
| $10.56 $10.28 | ▼ −2.65% | ▼ −2.59% | $9.56 (−9.47%) |
|
May 4, 2026
5w ago
|
Press Release
| $11.04 $11.11 | ▲ +0.63% | ▼ −0.75% | $9.56 (−13.41%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $11.00 $11.26 | ▲ +2.36% | ▲ +2.14% | $9.56 (−13.09%) |
|
Apr 21, 2026
7w ago
|
Press Release
| $10.33 $10.19 | ▼ −1.36% | ▼ −0.96% | $9.56 (−7.45%) |
|
Apr 13, 2026
8w ago
|
Press Release
| $11.24 $10.70 | ▼ −4.80% | ▼ −6.01% | $9.56 (−14.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access